Table 2. Associations between KRAS rs61764370 and outcome in ovarian and breast cancer.

Ovarian cancer analyses used OCAC data adjusted for age at diagnosis (overall survival only), the five European principal components, histology (serous, mucinous, endometrioid, clear cell, and other epithelial), grade (low versus high), FIGO stage (I–IV), residual disease after debulking surgery (nil versus any), and stratified by study; breast cancer analyses used BCAC data adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant hormonal and/or chemotherapy and was stratified by study; analyses for BRCA1 and BRCA2 mutation carriers used CIMBA data adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant hormonal and/or chemotherapy, and preventive bilateral oophorectomy and was stratified by study; 95% CI, 95% confidence interval.

	No. of patients	No. of events	Hazard ratio (95% CI)	p-Value
Ovarian cancer
Overall survival
All patients	3096	1421	0.94 (0.83–1.07)	0.38
Patients who were suboptimally   debulked after cytoreductive   surgery	1114	784	0.94 (0.78–1.13)	0.50
Post-menopausal patients > 52   years	2226	1276	0.97 (0.84–1.12)	0.70
Progression-free survival
All patients	3096	2144	1.01 (0.90–1.13)	0.84
Patients who were suboptimally   debulked after cytoreductive   surgery	1114	961	1.03 (0.87–1.21)	0.74
Post-menopausal patients >52   years	2226	1603	1.02 (0.90–1.16)	0.76
Breast cancer
Overall survival
All patients	28,471	3013	0.96 (0.87–1.06)	0.38
ER-positive patients	20,071	1754	0.96 (0.85–1.10)	0.58
ER-negative patients	4778	771	0.97 (0.81–1.18)	0.78
Breast cancer-specific survival
All patients	28,471	1693	0.95 (0.83–1.08)	0.40
Overall survival
BRCA1 mutation carriers	1706	241	0.72 (0.48–1.08)	0.11
BRCA2 mutation carriers	917	162	0.98 (0.65–1.46)	0.90